drugset / Trial / NCT01281488

Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors

NCT01281488

RandomizedSingle-groupSingle-blindTreatment

Summary

RATIONALE: Using fluorescence imaging may determine the extent of kidney tumors and help in planning surgery. PURPOSE: This phase I trial is studying the best way to give indocyanine green (ICG) fluorescence imaging in finding tumors in patients with kidney tumors

Timeline

Start
2011-10-20
Primary completion
2017-10-09
Completion
2017-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 0.018 mg/kg Intravenous
Subject Indocyanine Green Diagnostic / imaging agent 0.036 mg/kg Intravenous
Subject Indocyanine Green Diagnostic / imaging agent 0.07 mg/kg Intravenous
Subject Indocyanine Green Diagnostic / imaging agent 0.14 mg/kg Intravenous
Subject Indocyanine Green Diagnostic / imaging agent 0.21 mg/kg Intravenous

Indications